Parbendazole is a potent inhibitor of microtubule assembly that was studied as an anthelmintic agent. Information about the current use of this drug is not available.

Famotine, 1 -(p-chlorophenoxymethyl)-3,4-dihydroisoquinoline (UK 2054), is an antiviral compound.

FILIPIN is a complex of polyene macrolides obtained from Streptomyces filipinensis. The complex consists of four components: filipin I (4%), II (25%), III (53%), and IV (18%). Filipin III alters membrane function by interfering with membrane sterols, inhibits mitochondrial respiration, and is proposed as an antifungal agent. It is widely used as a marker for detection and quantification of cholesterol in cellular membranes.

Hexedine has been used as an antimicrobial agent and drug constituent. Information about the current use of this drug is not available.

Tibrofan is a non-peptide integrin αIIb/β3 receptor inhibitor and is usually used in combination with heparin to help prevent blood clotting.

Fiacitabine, also known as FIAC, is a pyrimidine nucleoside, which had been in phase II clinical trilas for the treatment Cytomegalovirus infections and Herpes simplex virus infections. However, these researches have been discontinued. It was also shown the inhibitor activity of FIAC against the DNA polymerase of hepadnaviruses.

Sulfacecole is an isoxazolylsulfanilamide derivative patented by Hoffmann -La Roche, F., und Co., A.-G. as antibacterial agent.

Cadazolid is a new antibiotic in development for the treatment of Clostridium difficile-associated diarrhea. Cadazolid is active against all (including linezolid- and moxifloxacin-resistant) Clostridium difficile strains. In phase I and II clinical trials, cadazolid was shown to be safe, well tolerated, and efficacious positioning itself as a potential future viable therapeutic option for CDI. Using a series of macromolecular labeling, in vitro transcription/translation, and topoisomerase studies, it was determined that protein synthesis inhibition via the oxazolidinone moiety is the primary mechanism of action of cadazolid. Cadazolid is in phase III clinical trials by Actelion Pharmaceuticals for the treatment of Clostridium difficile infection. The US FDA has designated cadazolid as both a Qualified Infectious Disease Product (QIDP) and a Fast Track development program for this indication.